Rohto PharmaceuticalLtd（RPHC.F）株式概要ロート製薬株式会社は、医薬品、化粧品、機能性食品を製造し、世界中で販売している。 詳細RPHC.F ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長1/6過去の実績3/6財務の健全性5/6配当金4/6報酬当社が推定した公正価値より37.6%で取引されている 収益は年間4.93%増加すると予測されています 過去1年間で収益は10.5%増加しました アナリストらは、株価が26.2%上昇するだろうとほぼ一致している。 リスク分析株式の流動性は非常に低い 不安定な配当実績 すべてのリスクチェックを見るRPHC.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$15.0017.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0443b2016201920222025202620282031Revenue JP¥442.9bEarnings JP¥44.1bAdvancedSet Fair ValueView all narrativesRohto Pharmaceutical Co.,Ltd. 競合他社InterparfumsSymbol: NasdaqGS:IPARMarket cap: US$2.9be.l.f. BeautySymbol: NYSE:ELFMarket cap: US$3.1bBellRing BrandsSymbol: NYSE:BRBRMarket cap: US$1.1bHerbalifeSymbol: NYSE:HLFMarket cap: US$1.2b価格と性能株価の高値、安値、推移の概要Rohto PharmaceuticalLtd過去の株価現在の株価JP¥15.0052週高値JP¥16.3052週安値JP¥14.34ベータ-0.471ヶ月の変化-1.32%3ヶ月変化4.60%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化14.07%最新ニュースお知らせ • May 16Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2026Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2026.お知らせ • May 09Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Rohto Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2026 results on May 13, 2026お知らせ • Mar 26Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 1,500,000 shares, representing 0.66% for ¥3,000 million.Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 1,500,000 shares, representing 0.66% of its share capital, for ¥3,000 million. The purpose of the program is to improve capital efficiency and enable the flexible execution of capital policies. The program will expire on December 31, 2026. As of March 26, 2026, the company had 225,964,340 shares in issue (excluding treasury stock) and 10,213,970 shares in treasury.お知らせ • Jan 08Rohto Pharmaceutical Co.,Ltd. (TSE:4527) entered into a share acquisition agreement to acquire 51% stake in Thann Oryza Company Limited from Thitipat Suppattranont and others.Rohto Pharmaceutical Co.,Ltd. (TSE:4527) entered into a share acquisition agreement to acquire 51% stake in Thann Oryza Company Limited from Thitipat Suppattranont and others on January 7, 2026. The expected completion of the transaction is March 31, 2026.お知らせ • Dec 04Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2026 Results on Feb 12, 2026Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2026 results on Feb 12, 2026お知らせ • Aug 28Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2026 Results on Nov 13, 2025Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2026 results on Nov 13, 2025最新情報をもっと見るRecent updatesお知らせ • May 16Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2026Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2026.お知らせ • May 09Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Rohto Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2026 results on May 13, 2026お知らせ • Mar 26Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 1,500,000 shares, representing 0.66% for ¥3,000 million.Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 1,500,000 shares, representing 0.66% of its share capital, for ¥3,000 million. The purpose of the program is to improve capital efficiency and enable the flexible execution of capital policies. The program will expire on December 31, 2026. As of March 26, 2026, the company had 225,964,340 shares in issue (excluding treasury stock) and 10,213,970 shares in treasury.お知らせ • Jan 08Rohto Pharmaceutical Co.,Ltd. (TSE:4527) entered into a share acquisition agreement to acquire 51% stake in Thann Oryza Company Limited from Thitipat Suppattranont and others.Rohto Pharmaceutical Co.,Ltd. (TSE:4527) entered into a share acquisition agreement to acquire 51% stake in Thann Oryza Company Limited from Thitipat Suppattranont and others on January 7, 2026. The expected completion of the transaction is March 31, 2026.お知らせ • Dec 04Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2026 Results on Feb 12, 2026Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2026 results on Feb 12, 2026お知らせ • Aug 28Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2026 Results on Nov 13, 2025Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2026 results on Nov 13, 2025お知らせ • Jun 03Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2026 Results on Aug 06, 2025Rohto Pharmaceutical Co.,Ltd. announced that they will report Q1, 2026 results on Aug 06, 2025お知らせ • May 13Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 26, 2025Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 26, 2025.お知らせ • Mar 01Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Rohto Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2025 results on May 13, 2025お知らせ • Feb 27Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 2,430,000 shares, representing 1.07% for ¥5,000 million.Rohto Pharmaceutical Co., Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 2,430,000 shares, representing 1.07% of its issued share capital, for a total cost of up to ¥5,000 million. The plan will continue until April 30, 2025.お知らせ • Feb 26Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 2,430,000 shares, representing 1.07% for ¥5,000 million.Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 2,430,000 shares, representing 1.07% of its share capital, for ¥5,000 million. The purpose of the program is to improve ROE and earnings per share (EPS), mitigate the short-term impact on the supply and demand of its shares from the issuance of Euro-yen convertible bonds with stock acquisition rights due in 2032, and facilitate fund procurement. The program will expire on April 30, 2025. As of December 31, 2024, the company had 228,138,738 shares in issue (excluding treasury stock) and 8,039,572 shares in treasury.お知らせ • Feb 12Rohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2025Rohto Pharmaceutical Co.,Ltd. revised dividend guidance for the fiscal Year Ending March 31, 2025. For the year, the company expects dividend of JPY 20.00 per share compared to JPY 17.00 per share a year ago. Reasons for the revisions: Consistently and continually returning to shareholders the profits earned through business activities is one of the highest priorities. The fundamental policy is to pay a dividend based on results of operations. Based on the earnings forecast for the fiscal year ending March 31, 2025 (April 1, 2024 to March 31, 2025), to enhance the return of profits to shareholders, for said fiscal year, the Company has decided to increase the year-end dividend by JPY 3 to JPY 20 per share. As such, the total annual dividend will be JPY 36 per share.お知らせ • Nov 29Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2025 Results on Feb 12, 2025Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2025 results on Feb 12, 2025お知らせ • Aug 28Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2025 Results on Nov 13, 2024Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2025 results on Nov 13, 2024お知らせ • Aug 07+ 1 more updateRohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Second Quarter-End and Full Fiscal Year Ending March 31, 2025Rohto Pharmaceutical Co.,Ltd. revised dividend guidance for the second quarter-end and full fiscal year ending March 31, 2025. For the second quarter-end the company now expects to pay dividend of JPY 16.00 per share against previous guidance of JPY 15.00 per share. For the year, the company now expects to pay dividend of JPY 17.00 per share against previous guidance of JPY 15.00 per share.お知らせ • Jun 17Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Aug 07, 2024Rohto Pharmaceutical Co.,Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024お知らせ • Jun 08Rohto Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Mono chem-pharm Produkte Gmbh for €30 million.Rohto Pharmaceutical Co.,Ltd. agreed to acquire additional 51% stake in Mono chem-pharm Produkte Gmbh for €30 million on June 6, 2024.お知らせ • May 15Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024.お知らせ • May 11Rohto Pharmaceutical Co.,Ltd. to Report Q4, 2024 Results on May 13, 2024Rohto Pharmaceutical Co.,Ltd. announced that they will report Q4, 2024 results on May 13, 2024お知らせ • Apr 05Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million on April 4, 2024. Eu Yan Sang International has net assets of SGD 149.9 million, total assets of SGD 268.1 million, sales of SGD 297.3 million, net income of SGD 18.7 million and core EBITDA of SGD 42.2 million as of June 30, 2023. Upon the fulfillment of the condition to the Share Acquisition, we will conduct a mandatory general offer for the remaining 14% of the issued ordinary shares of EYS The transaction is expected to complete by June 30, 2024.お知らせ • Dec 28Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2024 results on Feb 09, 2024お知らせ • Nov 12Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024Rohto Pharmaceutical Co.,Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2024. The company expects net sales to be JPY 270,000 million, Operating profit to be JPY 38,500 million, profit attributable to owners of parent to be JPY 29,000 million or JPY 127.12 per basic share.お知らせ • Nov 11+ 1 more updateRohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024Rohto Pharmaceutical Co.,Ltd. provides dividend guidance for the full year ending March 31, 2024. The company expects to pay JPY 15.00 against JPY 12.00 reported a year ago.お知らせ • Oct 01Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2024 results on Nov 10, 2023お知らせ • Jul 06Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Aug 09, 2023Rohto Pharmaceutical Co.,Ltd. announced that they will report Q1, 2024 results on Aug 09, 2023お知らせ • May 14Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023.お知らせ • Feb 20+ 1 more updateRohto Pharmaceutical Co.,Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023Rohto Pharmaceutical Co.,Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects revised net sales of JPY 236,000 million, operating profit of JPY 33,000 million, profit attributable to owners of parent of JPY 24,000 million and net income per share of JPY 105.20 compared to previously expected net sales of JPY 230,000 million, operating profit of JPY 31,000 million, profit attributable to owners of parent of JPY 22,000 million and net income per share of JPY 96.43.お知らせ • Jan 09Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Feb 13, 2023Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2023 results on Feb 13, 2023株主還元RPHC.FUS Personal ProductsUS 市場7D0%-7.1%0.3%1Yn/a-20.3%26.2%株主還元を見る業界別リターン: RPHC.FがUS Personal Products業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: RPHC.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is RPHC.F's price volatile compared to industry and market?RPHC.F volatilityRPHC.F Average Weekly Movementn/aPersonal Products Industry Average Movement7.7%Market Average Movement7.2%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.0%安定した株価: RPHC.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のRPHC.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト18999,144Hidetoshi Segiwww.rohto.co.jpロート製薬は医薬品、化粧品、機能性食品を製造し、世界中で販売している。目薬、コンタクトレンズケア、洗眼液などのアイケア製品、洗顔、ローション、クリームなどのフェイシャルケア製品を提供している。また、皮膚用薬・薬用化粧品、リップクリーム、日焼け止め、機能性化粧品などの医薬品、消化薬・生薬などの内服薬、再生薬、眼科薬・皮膚科薬・胃腸薬・診断薬などのOTC医薬品、漢方薬、サプリメントなども提供している。また、美容・健康サービスを提供するビューティーカウンターの運営、診断薬の製造・販売、投資運用サービス、開発・製造受託サービスも行っている。旧社名は山田製薬で、1949年9月にロート製薬株式会社に社名変更した。ロート製薬株式会社は1899年に設立され、大阪に本社を置いている。もっと見るRohto Pharmaceutical Co.,Ltd. 基礎のまとめRohto PharmaceuticalLtd の収益と売上を時価総額と比較するとどうか。RPHC.F 基礎統計学時価総額US$3.28b収益（TTM）US$214.08m売上高(TTM)US$2.15b15.3xPER（株価収益率1.5xP/SレシオRPHC.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計RPHC.F 損益計算書（TTM）収益JP¥343.73b売上原価JP¥151.03b売上総利益JP¥192.70bその他の費用JP¥158.45b収益JP¥34.25b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）151.56グロス・マージン56.06%純利益率9.96%有利子負債／自己資本比率16.5%RPHC.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.2%現在の配当利回り30%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/03 03:52終値2026/05/14 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Rohto Pharmaceutical Co.,Ltd. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Mitsuko MiyasakoBarclaysKentaro HosodaBofA Global ResearchHiroki WatanabeCitigroup Inc9 その他のアナリストを表示
お知らせ • May 16Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2026Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2026.
お知らせ • May 09Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Rohto Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2026 results on May 13, 2026
お知らせ • Mar 26Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 1,500,000 shares, representing 0.66% for ¥3,000 million.Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 1,500,000 shares, representing 0.66% of its share capital, for ¥3,000 million. The purpose of the program is to improve capital efficiency and enable the flexible execution of capital policies. The program will expire on December 31, 2026. As of March 26, 2026, the company had 225,964,340 shares in issue (excluding treasury stock) and 10,213,970 shares in treasury.
お知らせ • Jan 08Rohto Pharmaceutical Co.,Ltd. (TSE:4527) entered into a share acquisition agreement to acquire 51% stake in Thann Oryza Company Limited from Thitipat Suppattranont and others.Rohto Pharmaceutical Co.,Ltd. (TSE:4527) entered into a share acquisition agreement to acquire 51% stake in Thann Oryza Company Limited from Thitipat Suppattranont and others on January 7, 2026. The expected completion of the transaction is March 31, 2026.
お知らせ • Dec 04Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2026 Results on Feb 12, 2026Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2026 results on Feb 12, 2026
お知らせ • Aug 28Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2026 Results on Nov 13, 2025Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2026 results on Nov 13, 2025
お知らせ • May 16Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2026Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2026.
お知らせ • May 09Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Rohto Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2026 results on May 13, 2026
お知らせ • Mar 26Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 1,500,000 shares, representing 0.66% for ¥3,000 million.Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 1,500,000 shares, representing 0.66% of its share capital, for ¥3,000 million. The purpose of the program is to improve capital efficiency and enable the flexible execution of capital policies. The program will expire on December 31, 2026. As of March 26, 2026, the company had 225,964,340 shares in issue (excluding treasury stock) and 10,213,970 shares in treasury.
お知らせ • Jan 08Rohto Pharmaceutical Co.,Ltd. (TSE:4527) entered into a share acquisition agreement to acquire 51% stake in Thann Oryza Company Limited from Thitipat Suppattranont and others.Rohto Pharmaceutical Co.,Ltd. (TSE:4527) entered into a share acquisition agreement to acquire 51% stake in Thann Oryza Company Limited from Thitipat Suppattranont and others on January 7, 2026. The expected completion of the transaction is March 31, 2026.
お知らせ • Dec 04Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2026 Results on Feb 12, 2026Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2026 results on Feb 12, 2026
お知らせ • Aug 28Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2026 Results on Nov 13, 2025Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2026 results on Nov 13, 2025
お知らせ • Jun 03Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2026 Results on Aug 06, 2025Rohto Pharmaceutical Co.,Ltd. announced that they will report Q1, 2026 results on Aug 06, 2025
お知らせ • May 13Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 26, 2025Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 26, 2025.
お知らせ • Mar 01Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Rohto Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2025 results on May 13, 2025
お知らせ • Feb 27Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 2,430,000 shares, representing 1.07% for ¥5,000 million.Rohto Pharmaceutical Co., Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 2,430,000 shares, representing 1.07% of its issued share capital, for a total cost of up to ¥5,000 million. The plan will continue until April 30, 2025.
お知らせ • Feb 26Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces an Equity Buyback for 2,430,000 shares, representing 1.07% for ¥5,000 million.Rohto Pharmaceutical Co.,Ltd. (TSE:4527) announces a share repurchase program. Under the program, the company will repurchase up to 2,430,000 shares, representing 1.07% of its share capital, for ¥5,000 million. The purpose of the program is to improve ROE and earnings per share (EPS), mitigate the short-term impact on the supply and demand of its shares from the issuance of Euro-yen convertible bonds with stock acquisition rights due in 2032, and facilitate fund procurement. The program will expire on April 30, 2025. As of December 31, 2024, the company had 228,138,738 shares in issue (excluding treasury stock) and 8,039,572 shares in treasury.
お知らせ • Feb 12Rohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2025Rohto Pharmaceutical Co.,Ltd. revised dividend guidance for the fiscal Year Ending March 31, 2025. For the year, the company expects dividend of JPY 20.00 per share compared to JPY 17.00 per share a year ago. Reasons for the revisions: Consistently and continually returning to shareholders the profits earned through business activities is one of the highest priorities. The fundamental policy is to pay a dividend based on results of operations. Based on the earnings forecast for the fiscal year ending March 31, 2025 (April 1, 2024 to March 31, 2025), to enhance the return of profits to shareholders, for said fiscal year, the Company has decided to increase the year-end dividend by JPY 3 to JPY 20 per share. As such, the total annual dividend will be JPY 36 per share.
お知らせ • Nov 29Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2025 Results on Feb 12, 2025Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2025 results on Feb 12, 2025
お知らせ • Aug 28Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2025 Results on Nov 13, 2024Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2025 results on Nov 13, 2024
お知らせ • Aug 07+ 1 more updateRohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Second Quarter-End and Full Fiscal Year Ending March 31, 2025Rohto Pharmaceutical Co.,Ltd. revised dividend guidance for the second quarter-end and full fiscal year ending March 31, 2025. For the second quarter-end the company now expects to pay dividend of JPY 16.00 per share against previous guidance of JPY 15.00 per share. For the year, the company now expects to pay dividend of JPY 17.00 per share against previous guidance of JPY 15.00 per share.
お知らせ • Jun 17Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Aug 07, 2024Rohto Pharmaceutical Co.,Ltd. announced that they will report Q1, 2025 results on Aug 07, 2024
お知らせ • Jun 08Rohto Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Mono chem-pharm Produkte Gmbh for €30 million.Rohto Pharmaceutical Co.,Ltd. agreed to acquire additional 51% stake in Mono chem-pharm Produkte Gmbh for €30 million on June 6, 2024.
お知らせ • May 15Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024.
お知らせ • May 11Rohto Pharmaceutical Co.,Ltd. to Report Q4, 2024 Results on May 13, 2024Rohto Pharmaceutical Co.,Ltd. announced that they will report Q4, 2024 results on May 13, 2024
お知らせ • Apr 05Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million on April 4, 2024. Eu Yan Sang International has net assets of SGD 149.9 million, total assets of SGD 268.1 million, sales of SGD 297.3 million, net income of SGD 18.7 million and core EBITDA of SGD 42.2 million as of June 30, 2023. Upon the fulfillment of the condition to the Share Acquisition, we will conduct a mandatory general offer for the remaining 14% of the issued ordinary shares of EYS The transaction is expected to complete by June 30, 2024.
お知らせ • Dec 28Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2024 results on Feb 09, 2024
お知らせ • Nov 12Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024Rohto Pharmaceutical Co.,Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2024. The company expects net sales to be JPY 270,000 million, Operating profit to be JPY 38,500 million, profit attributable to owners of parent to be JPY 29,000 million or JPY 127.12 per basic share.
お知らせ • Nov 11+ 1 more updateRohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024Rohto Pharmaceutical Co.,Ltd. provides dividend guidance for the full year ending March 31, 2024. The company expects to pay JPY 15.00 against JPY 12.00 reported a year ago.
お知らせ • Oct 01Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023Rohto Pharmaceutical Co.,Ltd. announced that they will report Q2, 2024 results on Nov 10, 2023
お知らせ • Jul 06Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Aug 09, 2023Rohto Pharmaceutical Co.,Ltd. announced that they will report Q1, 2024 results on Aug 09, 2023
お知らせ • May 14Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023.
お知らせ • Feb 20+ 1 more updateRohto Pharmaceutical Co.,Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023Rohto Pharmaceutical Co.,Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects revised net sales of JPY 236,000 million, operating profit of JPY 33,000 million, profit attributable to owners of parent of JPY 24,000 million and net income per share of JPY 105.20 compared to previously expected net sales of JPY 230,000 million, operating profit of JPY 31,000 million, profit attributable to owners of parent of JPY 22,000 million and net income per share of JPY 96.43.
お知らせ • Jan 09Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Feb 13, 2023Rohto Pharmaceutical Co.,Ltd. announced that they will report Q3, 2023 results on Feb 13, 2023
